Compare Charles River Laboratories Intl. Inc (CRL) vs Mattel Inc (MAT) Price & Performance

Charles River Laboratories (CRL) trades at $284.37, up 2.66% today and near its 52-week high, reflecting strong bullish momentum. The stock has consistently beaten earnings estimates in recent quarters, including a Q2 2026 EPS of $3.02 versus $2.77 expected, and the company raised its full-year guidance. Despite negative net income margins, operating cash flow remains robust at $738 million in 2025. Analyst sentiment is overwhelmingly positive with 26 buy ratings and a consensus price target of $277.29.

The outlook is supported by improving biotech demand and cost controls, but high valuation multiples and recent insider selling pose risks. Earnings growth and margin expansion are key catalysts, though profitability challenges and macroeconomic sensitivity could pressure the stock. Investors should weigh strong technicals and analyst support against fundamental weaknesses and execution risks.

Mattel (MAT) trades at $14.76, up 0.14%, with a bullish technical signal from moving averages. The company reported mixed Q2 2026 results with a 10% revenue beat but an earnings miss, reflecting margin pressure from higher costs. Valuation appears reasonable with a P/E of 11.22 and P/S of 0.84, while profitability metrics like a 7.78% net margin and 20.5% ROE remain solid. Recent news highlights growth from toy-based films and adult collectors, though competitive and cost challenges persist.

The outlook is cautiously optimistic, supported by brand strength and entertainment initiatives, but near-term earnings volatility and discretionary spending sensitivity pose risks. Analyst consensus leans Buy with a $14.00 price target, suggesting modest upside potential from current levels amid ongoing execution scrutiny.